 ISELIN, N.J., Jan. 04, 2022 GLOBE NEWSWIRE -- Outlook Therapeutics, Inc. Nasdaq: OTLK, a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that C. Russell Trenary III, President and Chief Executive Officer of Outlook Therapeutics, will participate in a fireside chat at the virtual H.C. Wainwright BioConnect Conference taking place January 10-13, 2022. 